Healthcare > Pharmaceuticals & Biotechnology
•2430 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2430)
| Company | Market Cap | Price |
|---|---|---|
|
CRDL
Cardiol Therapeutics Inc.
Cardiol Therapeutics' lead drug is a cardiovascular therapy targeting heart disease.
|
$103.34M |
$1.24
+11.71%
|
|
GOSS
Gossamer Bio, Inc.
Inhaled seralutinib represents a drug-delivery platform that concentrates therapy in the lungs to treat pulmonary hypertension, a major differentiator.
|
$103.23M |
$0.44
+1.60%
|
|
COYA
Coya Therapeutics, Inc.
COYA's autologous regulatory T cell therapy program (COYA 101) represents a direct cell therapy product line.
|
$100.02M |
$4.79
+6.92%
|
|
ANTX
AN2 Therapeutics, Inc.
Epetraborole and AN2-502998 are oral small-molecule therapeutics developed on the company's boron chemistry platform.
|
$98.92M |
$3.61
+14.97%
|
|
XTNT
Xtant Medical Holdings, Inc.
Xtant operates as an OEM/contract manufacturer for orthobiologic and implant products.
|
$97.35M |
$0.73
-6.45%
|
|
ANIX
Anixa Biosciences, Inc.
CER-T CAR-T therapy is a direct cell therapy product focused on oncology.
|
$97.13M |
$2.92
+3.00%
|
|
ADVM
Adverum Biotechnologies, Inc.
Lead program Ixo-vec is a gene therapy for an ocular indication, placing Adverum in the Biotech - Gene Therapy category.
|
$91.49M |
$4.38
+0.34%
|
|
ALXO
ALX Oncology Holdings Inc.
ALX Oncology explicitly focuses on cancer therapies (immuno-oncology), placing it under Biotech - Oncology.
|
$90.54M |
$1.68
-0.30%
|
|
MXCT
MaxCyte, Inc.
Biotech - Cell Therapy category aligns with MaxCyte's role enabling cell therapies via transfection and processing platforms.
|
$90.44M |
$0.85
+3.94%
|
|
TENX
Tenax Therapeutics, Inc.
TNX-103 levosimendan is a cardiovascular drug candidate in Phase 3 for PH-HFpEF, making Cardiovascular Drugs the direct product category.
|
$90.22M |
$14.45
+7.20%
|
|
SLSN
Solesence, Inc. Common Stock
Solésence operates as a contract development and manufacturing organization (CDMO) for beauty products, matching Contract Manufacturing Organizations.
|
$90.22M |
$1.24
-3.13%
|
|
SGMO
Sangamo Therapeutics, Inc.
Core platform enabling genomic medicine via gene therapy and genome regulation (ZF/ZFR) technology.
|
$88.16M |
$0.25
-7.96%
|
|
CBUS
Cibus, Inc.
Reported contract research revenue indicates direct R&D services provided to clients alongside platform licensing.
|
$86.31M |
$1.59
+11.54%
|
|
IMMP
Immutep Limited
Immutep is focused on immunology therapeutics, including LAG-3 modulation for cancer and autoimmune diseases.
|
$85.29M |
$0.58
+0.50%
|
|
CSBR
Champions Oncology, Inc.
Company provides outsourced drug development and preclinical/clinical research services to biopharma (CRO-style).
|
$83.80M |
$5.89
-3.36%
|
|
ATYR
aTyr Pharma, Inc.
Efzofitimod is a biologic immunomodulator addressing inflammation in ILD, aligning with Immunology Therapeutics.
|
$83.62M |
$0.86
+3.01%
|
|
TIL
Instil Bio, Inc.
Instil Bio's lead candidate AXN-2510/IMM2510 is a bispecific antibody, placing the company squarely in the Bispecific Antibodies investable theme.
|
$82.97M |
$5.79
-52.89%
|
|
PLRX
Pliant Therapeutics, Inc.
Company's lead and mid-stage assets include oral small-molecule therapeutics (bexotegrast and PLN-101095) targeting integrin pathways.
|
$81.73M |
$1.34
+3.46%
|
|
ATHE
Alterity Therapeutics Limited
ATH434 is a small-molecule oral therapeutic in clinical development (Phase 2) for neurodegenerative disease, identified as Alterity's lead product.
|
$81.60M |
$4.34
+9.32%
|
|
MCRB
Seres Therapeutics, Inc.
SER-155 is a cultivated live biotherapeutic product (cell therapy) comprising a defined bacterial consortium.
|
$80.42M |
$8.87
+0.45%
|
|
VOR
Vor Biopharma Inc.
Vor Biopharma is focused on engineered cell therapies (eHSCs) and trem-cel, a cell therapy product.
|
$79.24M |
$12.50
+3.05%
|
|
ACET
Adicet Bio, Inc.
Directly develops allogeneic cell therapies (gamma delta T cells) for autoimmune diseases and cancer as its primary product platform.
|
$78.74M |
$8.25
+2.48%
|
|
GUTS
Fractyl Health, Inc. Common Stock
Rejuva gene therapy platform (RJVA-001) and related candidates (RJVA-002) classify as Biotech - Gene Therapy, a core product line aimed at durable disease modification.
|
$78.03M |
$0.56
+8.11%
|
|
GANX
Gain Therapeutics, Inc.
GT-02287 is a small-molecule therapeutic candidate, aligning with the major product category of oral small-molecule therapeutics.
|
$76.89M |
$2.14
+4.39%
|
|
IGMS
IGM Biosciences, Inc.
IGMS's engineered antibodies are monoclonal antibody therapeutics, a core product category.
|
$76.35M |
$1.27
|
|
BHST
BioHarvest Sciences Inc. Common Stock
BioHarvest operates a CDMO division providing contract development and manufacturing services for plant-based compounds.
|
$75.05M |
$4.35
+0.46%
|
|
XBIT
XBiotech Inc.
Company develops oncology therapies using True Human monoclonal antibodies, aligning with the Biotech - Oncology tag.
|
$75.00M |
$2.46
+1.44%
|
|
VANI
Vivani Medical, Inc.
Vivani's NanoPortal is a proprietary drug-implant platform enabling ultra long-acting, localized drug delivery.
|
$74.65M |
$1.30
+3.17%
|
|
PYPD
PolyPid Ltd.
D-PLEX100 leverages PolyPid's PLEX drug-delivery platform to provide localized, prolonged antibiotic release at the surgical site.
|
$74.20M |
$4.71
+1.18%
|
|
PMVP
PMV Pharmaceuticals, Inc.
PMVP is a biotech company focused on oncology, developing rezatapopt to restore p53 function in TP53-mutant cancers, representing its core product category.
|
$73.43M |
$1.39
+1.46%
|
|
FBIO
Fortress Biotech, Inc.
Fortress Biotech directly encompasses oncology-focused biotech through its portfolio (e.g., Mustang Bio) and related assets, aligning with Biotech - Oncology.
|
$73.25M |
$2.35
+0.21%
|
|
NRXP
NRx Pharmaceuticals, Inc.
NRx's pipeline centers on neuropsychiatric drug development (NRX-100, NRX-101) targeting suicidal depression and bipolar depression.
|
$71.65M |
$2.56
+1.99%
|
|
MNOV
MediciNova, Inc.
MN-166 (ibudilast) and MN-001 (tipelukast) are oral small-molecule therapeutics in MediciNova's development pipeline.
|
$71.61M |
$1.45
+0.69%
|
|
XGN
Exagen Inc.
Exagen's biomarker-based tests (e.g., AVISE CTD, SLE T-cell markers, RA33) align with companion diagnostics.
|
$69.80M |
$3.10
+1.64%
|
|
BYSI
BeyondSpring Inc.
BeyondSpring develops oncology therapeutics (Plinabulin) with a novel SIMBA mechanism, directly addressing cancer and CIN.
|
$69.77M |
$1.68
|
Showing page 17 of 25 (2430 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
